
A trial built to pre-empt small cell transformation in TP53/RB1-deficient, EGFR-mutant NSCLC still saw it in nearly half of its patients. The paper, led by Lena Morrill Gavarró and Helena Alexandra Yu, includes our faculty member Charles Rudin (@charlesrudin) among its authors. 🔬 Prospective trial: 1L osimertinib plus platinum and etoposide in EGFR-mutant, TP53/RB1-deficient NSCLC 📊 SCLC transformation in 5 of 11 patients despite SCLC-directed chemotherapy 📊 mPFS 11 mo; mOS 33 mo 📌 Profiling also found mesenchymal and squamous histologies, tied to progressive RB pathway disruption ⚠️ 11 patients and 1 arm, so no comparison with osimertinib alone Find the single-cell findings on mesenchymal and squamous change in our article. lungsummit.org/articles/sclc…




























